Teriparatide + Zoledronic Acid
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Osteoporosis, Osteopenia
Conditions
Osteoporosis, Osteopenia
Trial Timeline
Jul 1, 2008 → Dec 1, 2012
NCT ID
NCT01153425About Teriparatide + Zoledronic Acid
Teriparatide + Zoledronic Acid is a approved stage product being developed by Eli Lilly for Osteoporosis, Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01153425. Target conditions include Osteoporosis, Osteopenia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00927186 | Approved | Completed |
| NCT01153425 | Approved | Completed |
Competing Products
20 competing products in Osteoporosis, Osteopenia